Man Group’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-516,258
Closed -$66.2M 2226
2025
Q2
$66.2M Sell
516,258
-3,479
-0.7% -$361K 0.13% 174
2025
Q1
$46M Buy
519,737
+415,818
+400% +$40.6M 0.12% 210
2024
Q4
$9.06M Sell
103,919
-414,697
-80% -$38M 0.02% 763
2024
Q3
$48M Buy
518,616
+125,718
+32% +$12.5M 0.12% 199
2024
Q2
$42.3M Sell
392,898
-15,982
-4% -$1.6M 0.11% 214
2024
Q1
$38.8M Buy
408,880
+30,816
+8% +$2.64M 0.1% 231
2023
Q4
$34.9M Buy
+378,064
New +$24.5M 0.1% 239
2023
Q1
Sell
-6,911
Closed -$311K 749
2022
Q4
$303K Sell
6,911
-35,629
-84% -$1.71M ﹤0.01% 1647
2022
Q3
$2.8M Buy
+42,540
New +$2.73M 0.01% 951
2022
Q1
Sell
-42,797
Closed -$4.58M 2187
2021
Q4
$4.58M Sell
42,797
-17,238
-29% -$1.8M 0.01% 905
2021
Q3
$6.17M Sell
60,035
-558
-0.9% -$52K 0.02% 758
2021
Q2
$5.33M Buy
60,593
+45,847
+311% +$4.2M 0.02% 856
2021
Q1
$1.43M Sell
14,746
-54,067
-79% -$5.4M 0.01% 1206
2020
Q4
$7.72M Sell
68,813
-21,186
-24% -$2.23M 0.03% 561
2020
Q3
$8.34M Sell
89,999
-22,233
-20% -$1.71M 0.03% 553
2020
Q2
$8.75M Buy
112,232
+33,880
+43% +$2.29M 0.04% 406
2020
Q1
$4.58M Buy
78,352
+50,915
+186% +$3.28M 0.03% 527
2019
Q4
$2.2M Sell
27,437
-16,758
-38% -$1.25M 0.01% 1305
2019
Q3
$3.25M Sell
44,195
-8,801
-17% -$761K 0.01% 1072
2019
Q2
$5M Buy
52,996
+42,147
+388% +$3.48M 0.02% 950
2019
Q1
$868K Buy
10,849
+4,314
+66% +$319K ﹤0.01% 1618
2018
Q4
$352K Sell
6,535
-12,370
-65% -$752K ﹤0.01% 1692
2018
Q3
$1.48M Sell
18,905
-39,676
-68% -$2.76M 0.01% 1521
2018
Q2
$3.72M Buy
+58,581
New +$4.66M 0.02% 1087

Other funds holding BPMC

Man Group's BPMC Position: Q3 2025 in Review

Man Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 516,258 shares — an estimated $66.2M sold.

Man Group first reported a position in BPMC in Q2 2018 and held it in 24 quarters. The position peaked at $66.2M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Man Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Man Group sold 516,258 Blueprint Medicines shares in Q3 2025, an estimated $66.2M.
  • Man Group first reported a position in Blueprint Medicines in Q2 2018 and held it in 24 quarters.
  • Man Group's Blueprint Medicines position peaked at $66.2M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Man Group's 13F filing for Q3 2025, filed 14 Nov 2025.